Drug safety “virtual” surveillance sought by FDA
FDA will hold a public meeting to examine the feasibility of public-private partnerships to create a "virtual" product safety surveillance system based on existing datasets and collection activities. Topics will include the creation of "dynamic feedback loops" in which practitioners and patients fuel data collection and are provided with updated information after analysis. FDA is planning to devote user fee resources to overhaul its postmarketing surveillance efforts (1"The Pink Sheet" Jan. 15, 2007, p. 3). The meeting on the "Sentinel Network" will take place March 7-8 at the University System of Maryland Shady Grove Center in Rockville, Md...
You may also be interested in...
Can a false-claims suit be filed if doctors have different opinions about whether a treatment was necessary? The Supreme Court won’t say.
Despite turbulence in 2020 from the coronavirus pandemic as well as from difficulties relating to two of its key US generic launches, Hikma has reported solid full-year growth in both sales and profits across its business.
The firms' messenger RNA alliance inked back on 2013 is still very much ongoing but AstraZeneca decided to sell its considerable stake in the high-profile biotech to help finance its own pipeline.